Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Ionis Pharmaceuticals ( (IONS) ) is now available.
On August 21, 2025, Ionis Pharmaceuticals announced that the FDA approved DAWNZERA™ (donidalorsen) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older. DAWNZERA is the first RNA-targeted medicine for HAE, significantly reducing attack rates and offering a convenient dosing schedule. The approval was based on successful Phase 3 trial results, showing an 81% reduction in monthly HAE attack rates. This approval strengthens Ionis’ position in the market, offering a new treatment option for HAE patients, and is part of Ionis’ broader strategy to deliver life-changing medicines.
The most recent analyst rating on (IONS) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.
Spark’s Take on IONS Stock
According to Spark, TipRanks’ AI Analyst, IONS is a Neutral.
Ionis Pharmaceuticals’ overall stock score is primarily impacted by its financial challenges, including high leverage and negative cash flows. However, strong technical indicators and positive earnings call sentiment, driven by successful product launches and strategic execution, provide a counterbalance. Valuation remains a concern due to negative earnings, but positive corporate events support the company’s strategic direction.
To see Spark’s full report on IONS stock, click here.
More about Ionis Pharmaceuticals
Ionis Pharmaceuticals is a pioneer in RNA-targeted medicines, with a focus on neurology, cardiology, and other areas of high patient need. The company is dedicated to developing innovative RNA therapies and advancing new approaches in gene editing.
Average Trading Volume: 1,906,712
Technical Sentiment Signal: Buy
Current Market Cap: $6.77B
For a thorough assessment of IONS stock, go to TipRanks’ Stock Analysis page.